Sarepta Therapeutics, Inc. (SRPT): restructuring charge — Sarepta cuts 36% workforce, reports $513M Q2 revenue, agrees to ELEVIDYS black box warning

Sarepta Therapeutics, Inc.

Workforce reduction of ~36% (~500 employees); one-time charge of $32-37M in Q3 2025; annual cost savings of ~$400M.
Preliminary Q2 2025 net product revenue $513M: ELEVIDYS $282M, PMOs $231M; cash & investments ~$850M.
FDA requested black box warning for acute liver injury/failure in ELEVIDYS label; Sarepta agrees, resolving material issues for ambulant patients.
Pipeline reprioritized to focus on siRNA platform; most LGMD gene therapies paused, except SRP-9003 BLA expected H2 2025.
Executive changes: Ian Estepan as President/COO, Louise Rodino-Klapac as President R&D, Ryan Wong as CFO; Dallan Murray departs.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Sarepta Therapeutics, Inc. announced a restructuring with charges of between approximately $32 million and $37 million (approximately 36% of the Company's workforce).

Type: restructuring
Charge: between approximately $32 million and $37 million
Headcount: approximately 36% of the Company's workforce

Exact text from the filing

on July 14, 2025, the Board of Directors of the Company (the “Board”) approved a reduction in force, representing approximately 36% of the Company’s workforce. As a result of this reduction in force, the Company estimates that it will record a one-time charge in the third quarter of 2025 related to employee termination benefits, including severance, between approximately $32 million and $37 million

View on SEC.gov

2 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

Sarepta Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-096257

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.